

4017

Governance: C

FAKEEH CARE

Dr. Soliman Abdel Kader Fakeeh Hospital Co.

35.98 SAR / Share

As of: May 28, 2026

<p>40.0x</p> <p>P/E RATIO</p> <p>Trailing 12 Months</p>	<p>2.6x</p> <p>P/B RATIO</p> <p>Price to Book Value</p>	<p>0.8%</p> <p>DIVIDEND YIELD</p> <p>Annual Dividend / Share</p>	<p>8.28B</p> <p>SAR</p> <p>MARKET CAP</p> <p>Total Valuation</p>	<p>0.89</p> <p>BETA</p> <p>Systematic Risk Index</p>	<p>6.6%</p> <p>NET MARGIN</p> <p>Net Profit / Revenue</p>
----------------------------------------------------------------	----------------------------------------------------------------	-------------------------------------------------------------------------	-------------------------------------------------------------------------	-------------------------------------------------------------	------------------------------------------------------------------

Company Profile

Dr. Soliman Abdel Kader Fakeeh Hospital Company (the 'Parent Company') is a Saudi Joint Stock Company. The principal activity of the Group is managing, establishing and operating hospitals, clinics, medical, educational and training centers. In addition, the Group manages and operates medical services, analysis and radiology laboratories, and establishes pharmacies, wholesale and retail of medical equipment, maintenance of IT equipment, and software-related services. The Group operates primarily in the Kingdom of Saudi Arabia and has three reportable segments: medical services, education, and trading & retail business.

The Story

"Fakeeh Care is a premier Saudi healthcare and education provider balancing steady top-line growth with an aggressive capital reinvestment cycle that tests its near-term profitability."

Financial Metric	Value
Return on Capital (ROIC)	8.0%
Debt-to-Equity Ratio	15.4%
Sustainable Growth Rate	+11.2%

Growth Story

Fakeeh Care has demonstrated consistent top-line expansion, with revenues rising from 2,326,688,000 SAR in FY 2023 to 2,790,880,000 SAR in FY 2024, and reaching 3,090,245,000 SAR in FY 2025, with TTM revenue standing at 3,113,374,000 SAR. This growth is underpinned by an extraordinary five-year average reinvestment... [\[Read full story\]](#)

Corporate Governance Profile

Rating: C

We track 13 key governance disclosures in our database.

Profitability Dynamics

TTM EBIT of 275,626,000 SAR yields an operating margin of 8.85% and a net profit margin of 6.65%. While medical services remain the primary revenue driver, generating 657,257,000 SAR of the 724,147,000 SAR in segment revenue for the three months ended March 31, 2026, near-term profitability has faced pressure. Profit... [\[Read full story\]](#)

Risk & Capital Structure Factors

The primary risk for Fakeeh Care stems from its capital-intensive expansion and the associated debt burden. The company carries a latest total debt of 1,278,001,000 SAR against a cash balance of 126,411,000 SAR, though total cash and cash equivalents reached 421,911,000 SAR by March 31, 2026. Quarterly finance costs... [\[Read full story\]](#)

